ChemoCentryx, Inc. drug Avacopan has been accepted as a New Drug Application by the FDA for the treatment of anca vasculitis. The drug is administered through oral route and is formulated in such a way that it will block the complement 5a receptor (C5aR) on destructive inflammatory cells known as neutrophils. The NDA includes the clinical phase III trial of the drug. The report suggested that the drug was effective with few side-effects.